Pegcetacoplan Offers Potential Benefit in Post-Transplant C3

The phase 2 NOBLE trial shows pegcetacoplan reduces disease activity in post-transplant C3G and IC-MPGN, with benefits persisting through the 40-week double-blind period.

Related Keywords

Stockholm , Sweden , United States , American , Fadi Fakhouri , Caroline Baumal , European Renal Association Congress , University Of Lausanne Fadi Fakhouri , Apellis Pharmaceuticals Inc , Lausanne University Hospital , American Society Of Nephrology Kidney Week , Lausanne University , American Society , Nephrology Kidney Week , European Renal Association , Apellis Pharmaceuticals ,